1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

UCB's Bimzelx Close To Challenging Major Psoriasis Players

Recommended For EU Approval

 
• By Kevin Grogan

With the drug demonstrating superiority over approved psoriasis therapies such as Cosentyx, Stelara and Humira in clinical trials, UCB's bimekizumab will shortly compete against these well-entrenched rivals on the European market, following a thumbs-up from the CHMP. 

UCB
CHMP backing a big boost for Belgian group • Source: Archive

Having generated a hefty package of positive data, including wins in head-to-head trials with psoriasis market leaders such as Novartis AG's Cosentyx and Johnson & Johnson’s Stelara, UCB S.A.'s bimekizumab is finally set to cross the finishing line after being recommended for approval by EU regulators for psoriasis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

J&J Dreams Of ICONIC Status For Icotrokinra

 
• By Kevin Grogan

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.